TY - JOUR
T1 - Estimated Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared to Optimally Acenocoumarol Anticoagulated ‘Real-World’ in Patients With Atrial Fibrillation
AU - Esteve-Pastor, María Asunción
AU - Rivera-Caravaca, José Miguel
AU - Roldán, Vanessa
AU - Orenes-Piñero, Esteban
AU - Romiti, Giulio Francesco
AU - Romanazzi, Imma
AU - Bai, Ying
AU - Carmo, João
AU - Proietti, Marco
AU - Marín, Francisco
AU - Lip, Gregory
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as an alternative to vitamin K antagonists in atrial fibrillation (AF) patients but the comparative benefits between NOACs and optimally anticoagulated patients is unknown. We estimated the absolute benefit in clinical outcomes rates of real-world (RW) effect of NOACs in optimally anticoagulated AF patients with acenocoumarol. We included 1,361 patients stable on acenocoumarol with time in therapeutic range of 100% and 6.5 years of follow-up. Estimation of clinical events avoided was calculated applying hazard ratio, absolute and relative risk reduction from the RW meta-analysis. Compared to an optimally anticoagulated population, dabigatran 110mg had the highest estimated stroke reduction (0.97%/year vs 1.47%/year; p=0.002), and the benefit was higher than in RE-LY trial. For major bleeding, apixaban showed the highest estimated reduction (1.81%/year vs 2.83%/year; p<0.001). For mortality, the largest estimated reduction was with apixaban (2.68%/year). For gastrointestinal bleeding, only apixaban had a significant reduction compared to acenocoumarol (0.69%/year vs 1.10%/year; p=0.004), and the reduction was significantly higher than in ARISTOTLE trial. All NOACs showed significantly lower rates for intracranial haemorrhage and had a positive Net Clinical Benefit (NCB) compared to acenocoumarol. Apixaban showed the highest extended estimated NCB 2.64 (95%CI 2.34-2.96). In conclusion, in optimally acenocoumarol anticoagulated AF patients, estimated reductions in all clinical outcomes with various NOACs are evident, with the best effectiveness and safety profile with apixaban. Indeed, the estimated effect with “real world” NOACs would probably be higher than that seen in phase-III clinical trials.
AB - Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as an alternative to vitamin K antagonists in atrial fibrillation (AF) patients but the comparative benefits between NOACs and optimally anticoagulated patients is unknown. We estimated the absolute benefit in clinical outcomes rates of real-world (RW) effect of NOACs in optimally anticoagulated AF patients with acenocoumarol. We included 1,361 patients stable on acenocoumarol with time in therapeutic range of 100% and 6.5 years of follow-up. Estimation of clinical events avoided was calculated applying hazard ratio, absolute and relative risk reduction from the RW meta-analysis. Compared to an optimally anticoagulated population, dabigatran 110mg had the highest estimated stroke reduction (0.97%/year vs 1.47%/year; p=0.002), and the benefit was higher than in RE-LY trial. For major bleeding, apixaban showed the highest estimated reduction (1.81%/year vs 2.83%/year; p<0.001). For mortality, the largest estimated reduction was with apixaban (2.68%/year). For gastrointestinal bleeding, only apixaban had a significant reduction compared to acenocoumarol (0.69%/year vs 1.10%/year; p=0.004), and the reduction was significantly higher than in ARISTOTLE trial. All NOACs showed significantly lower rates for intracranial haemorrhage and had a positive Net Clinical Benefit (NCB) compared to acenocoumarol. Apixaban showed the highest extended estimated NCB 2.64 (95%CI 2.34-2.96). In conclusion, in optimally acenocoumarol anticoagulated AF patients, estimated reductions in all clinical outcomes with various NOACs are evident, with the best effectiveness and safety profile with apixaban. Indeed, the estimated effect with “real world” NOACs would probably be higher than that seen in phase-III clinical trials.
KW - non-vitamin K oral anticoagulants
KW - vitamin K antagonists
KW - atrial fibrillation
KW - real-world
U2 - 10.1016/j.amjcard.2018.05.012
DO - 10.1016/j.amjcard.2018.05.012
M3 - Article
SN - 0002-9149
JO - The American Journal of Cardiology
JF - The American Journal of Cardiology
ER -